

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addrigs: COMMISSIONER OF PATENTS AND TRADEMARKS / Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/875,440	06/05/2001	Christoph Reinhard	PP-01701.002	5034
759	90 09/27/2002	·		
Chiron Corporation Intellectual Property P.O. Box 8097 Emeryville, CA 94662-8097			EXAMINER	
			MCGARRY, SEAN	
			ART UNIT	PAPER NUMBER
	•		1635	7
			DATE MAILED: 09/27/2002	1

Please find below and/or attached an Office communication concerning this application or proceeding.

₽ 1		Application No.	Applicant(s)			
		09/875,440	REINHARD ET AL.			
	Office Action Summary	Examiner	Art Unit			
		Sean McGarry	1635			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status						
1)	Responsive to communication(s) filed on	. •				
2a)□		is action is non-final.				
3)						
Disposition of Claims						
4)⊠ Claim(s) <u>1-23</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
	Claim(s) is/are objected to.					
8) Claim(s) 1-23 are subject to restriction and/or election requirement.						
Application Papers						
9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
	1. Certified copies of the priority documents have been received.					
	2. Certified copies of the priority documents have been received in Application No					
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
2) Notic	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Inform	ary (PTO-413) Paper No(s) al Patent Application (PTO-152)			

Application/Control Number: 09/875,440

Art Unit: 1635

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-5, 9-16, and 19, drawn to NET-4 inhibitory antisense and ribozyme molecules, classifiable in class 536, subclass 24.5.
- II. Claims 1, 9, 10, 12, 17, and 19, drawn to NET-4 inhibitory proteins or polypeptides, classifiable in class 514, subclass 2.
- III. Claims 1, 9, 10, 12, 18, and 19, drawn to NET-4 inhibitory small molecules, classifiable in class 514, subclass 1.
- IV. Claims 1, 6, 7, 8, 9, and 10, drawn to NET-4 inhibitory antibodies, classifiable in class 424, subclass 130.1.
- V. Claims 21-23, drawn to a KIT comprising NET-4 probes, classifiable in class 536, subclass 24.33.
- Claim 1, 9, 10, 12, and 19 are generic to Groups I-IV and will be examined only so far as they read on the invention elected.

The inventions are distinct, each from the other because of the following reasons:

Inventions I-IV. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are different compounds that have different modes of operation and are distinct and independent chemical compositions composed of

Application/Control Number: 09/875,440

Art Unit: 1635

different chemical constituents where the compounds have different chemical and biological properties. For example, antisense inhibitors function by inhibiting the translation from and RNA, a protein inhibition may function as a dominant negative inhibitor of the targeted protein, the antibodies may function to physically impair a target protein function and a small molecule may inhibit a member of the target protein pathway.

Inventions I-VI and V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are mutually exclusive. The members of Groups I-IV are all NET-4 inhibitors and are not probes for NET-4 and would therefore not be used in the kit as claimed and the kit of Group V could not be used to inhibit NET_4 since the Kit does not include inhibitor, for example.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Application/Control Number: 09/875,440

Art Unit: 1635

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sean R McGarry whose telephone number is (703)305-7028. The examiner can normally be reached on M-Th (6:00-5:00).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader can be reached on (703) 308-0447. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

SRM September 26, 2002 SEAN MCGARRY PRIMARY EXAMINER

635